Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason A Powell

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
British Journal of Haematology|December 6, 2023
An orthotopic syngeneic mouse model of bortezomib-resistant multiple myelomaManjun Li, Melissa K Bennett, John Toubia, et al.
Cancer Research|December 17, 2005
FBXO31 is the chromosome 16q24.3 senescence gene, a candidate breast tumor suppressor, and a component of an SCF complexRaman Kumar, Paul M Neilsen, Joanne Crawford, et al.
The Journal of Biological Chemistry|February 17, 2009
14-3-3:Shc scaffolds integrate phosphoserine and phosphotyrosine signaling to regulate phosphatidylinositol 3-kinase activation and cell survivalEmma F Barry, Fernando A Felquer, Jason A Powell, et al.
The Biochemical Journal|October 26, 2019
Kelch-like protein 5-mediated ubiquitination of lysine 183 promotes proteasomal degradation of sphingosine kinase 1Jason A Powell, Melissa R Pitman, Julia R Zebol, et al.
The EMBO Journal|January 27, 2006
Growth factor pleiotropy is controlled by a receptor Tyr/Ser motif that acts as a binary switchMark A Guthridge, Jason A Powell, Emma F Barry, et al.
Genomics|September 6, 2002
Sequencing, transcript identification, and quantitative gene expression profiling in the breast cancer loss of heterozygosity region 16q24.3 reveal three potential tumor-suppressor genesJason A Powell, Alison E Gardner, Anthony J Bais, et al.
Cancer Research|June 17, 2010
Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancersKathryn G Roberts, Amanda M Smith, Fiona McDougall, et al.
Haematologica|July 2, 2015
Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient miceErwin M Lee, Dean Yee, Samantha J Busfield, et al.
Oncotarget|March 20, 2015
A selective ATP-competitive sphingosine kinase inhibitor demonstrates anti-cancer propertiesMelissa R Pitman, Jason A Powell, Carl Coolen, et al.
Neoplasia (New York, N.Y.)|November 26, 2021
Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibitionMelissa K Bennett, Manjun Li, Melinda N Tea, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
British Journal of Haematology|December 6, 2023
An orthotopic syngeneic mouse model of bortezomib-resistant multiple myelomaManjun Li, Melissa K Bennett, John Toubia, et al.
Cancer Research|December 17, 2005
FBXO31 is the chromosome 16q24.3 senescence gene, a candidate breast tumor suppressor, and a component of an SCF complexRaman Kumar, Paul M Neilsen, Joanne Crawford, et al.
The Journal of Biological Chemistry|February 17, 2009
14-3-3:Shc scaffolds integrate phosphoserine and phosphotyrosine signaling to regulate phosphatidylinositol 3-kinase activation and cell survivalEmma F Barry, Fernando A Felquer, Jason A Powell, et al.
The Biochemical Journal|October 26, 2019
Kelch-like protein 5-mediated ubiquitination of lysine 183 promotes proteasomal degradation of sphingosine kinase 1Jason A Powell, Melissa R Pitman, Julia R Zebol, et al.
The EMBO Journal|January 27, 2006
Growth factor pleiotropy is controlled by a receptor Tyr/Ser motif that acts as a binary switchMark A Guthridge, Jason A Powell, Emma F Barry, et al.
Genomics|September 6, 2002
Sequencing, transcript identification, and quantitative gene expression profiling in the breast cancer loss of heterozygosity region 16q24.3 reveal three potential tumor-suppressor genesJason A Powell, Alison E Gardner, Anthony J Bais, et al.
Cancer Research|June 17, 2010
Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancersKathryn G Roberts, Amanda M Smith, Fiona McDougall, et al.
Haematologica|July 2, 2015
Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient miceErwin M Lee, Dean Yee, Samantha J Busfield, et al.
Oncotarget|March 20, 2015
A selective ATP-competitive sphingosine kinase inhibitor demonstrates anti-cancer propertiesMelissa R Pitman, Jason A Powell, Carl Coolen, et al.
Neoplasia (New York, N.Y.)|November 26, 2021
Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibitionMelissa K Bennett, Manjun Li, Melinda N Tea, et al.
Pageof 4